Biomarkers for neurodegenerative diseases in regulatory decision‐making by the European Medicines Agency

Biomarkers for neurodegenerative diseases in regulatory decision‐making by the European Medicines Agency

Abstract INTRODUCTION Biomarkers (BMs) are valuable tools to facilitate early diagnosis of (subtypes of) diseases, improve patient selection and stratification, and detect therapeutic effects or safety concerns. This study explores the extent to which BMs are utilized in the development of treatment...

Full description

Saved in:
Bibliographic Details
Main Authors: Audrey M. M. Hermans, Elisabeth Bakker, Viktoriia Starokozhko, Loes den Otter, André J. A. Elferink, Angela Bradshaw, Lorenzo Guizzaro, Peter G. M. Mol, Anna M. G. Pasmooij
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Alzheimer’s & Dementia: Translational Research & Clinical Interventions
Subjects:
Alzheimer's disease
biomarker
European Medicines Agency
multiple sclerosis
neurodegenerative diseases
Parkinson's disease
Online Access:https://doi.org/10.1002/trc2.70072
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/trc2.70072

Similar Items